Online inquiry

IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4351MR)

This product GTTS-WQ4351MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL5RA gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000564.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3568
UniProt ID Q01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4351MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6849MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ9811MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ6705MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ702MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ7601MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ12511MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ11000MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ13351MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06801591
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW